Well Europe and then Japan and now Australia patent protection...

Well Europe and then Japan and now Australia patent protection granted. All that leaves is the US and all the big regions are covered.

There is no point having a ground breaking treatment unless you have the patent protection to back it up and be able to commercialise your success. The scrutiny of the patent offices are significant so this is undoubtedly a positive.

But the patent being granted while reminding everyone that the canine study supports the hypothesis that an oromucosal version of Anagrelide can reduce platelet count without the cardio toxic side effects is a great step forward by the company.

I suspect this opens up the communication from the company and we get that canine study result shortly.

We know that this opportunity is massive and this is a tick in the box in SUDA commercialising this. I wonder how many prospective partners are watching what SUDA is doing and the steps forward they are taking regarding this project?

For a $15m market cap with plenty of cash in the bank it seems like there is plenty of upside to me